Bristol-Myers files for Japanese approval of first all-oral hep C treatment; Novogen, Yale tackle ovarian cancer drug delivery together;

> Bristol-Myers Squibb ($BMY) filed with Japanese health regulators to approve its all-oral hepatitis C treatment, the first of its kind. Story

> Novogen and Yale launched a joint venture to develop treatments for ovarian cancer that use a delivery model created by a Yale professor. More

> Zogenix entered a development and option agreement with Altus Formulation for Zogenix's extended-release hydrocodone and Altus' delivery platform. More

> Aphios won a U.S. patent for its nanoencapsulated oral delivery platform for cannabinoids to treat pain in cancer and AIDS patients. More

Suggested Articles

Kala Pharma's Eysuvis on Tuesday became the first and only corticosteroid approved to treat short-term signs and symptoms of dry eye disease.

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.